Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions
- HER2-Positive Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
Interventions
- DRUG: Aromatase Inhibition Therapy
- DRUG: Carboplatin
- OTHER: Cytology Specimen Collection Procedure
- DRUG: Docetaxel
- DRUG: Goserelin Acetate
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pertuzumab
- OTHER: Quality-of-Life Assessment
- PROCEDURE: Therapeutic Conventional Surgery
- BIOLOGICAL: Trastuzumab
- RADIATION: Whole Breast Irradiation
Sponsor
National Cancer Institute (NCI)
Collaborators